Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
104 studies found for:    "Adenoid cystic carcinoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Adenoid cystic carcinoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of RAD001 in Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: RAD001
2 Completed
Has Results
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: doxorubicin and bortezomib
3 Recruiting Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Cetuximab
4 Completed Dovitinib in Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: TKI258 (Dovitinib):
5 Recruiting Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Lenvatinib
6 Completed Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Dovitinib (TKI258)
7 Enrolling by invitation Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Brontictuzumab
8 Active, not recruiting Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Regorafenib
9 Completed Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AG-013736 (AXITINIB)
10 Recruiting A Study of Apatinib in Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Apatinib Mesylate
11 Not yet recruiting Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Interventions: Drug: Apatinib;   Radiation: Particle Therapy
12 Recruiting Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
Condition: Adenoid Cystic Carcinomas of the Salivary Glands
Intervention: Drug: Lenvatinib
13 Completed A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Conditions: Adenoid Cystic Carcinoma;   Salivary Gland Cancer
Intervention: Drug: Sunitinib
14 Not yet recruiting Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety
Condition: Adenocystic Carcinoma
Intervention: Drug: Chidamide
15 Completed A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Conditions: Recurrent Adenoid Cystic Carcinoma of the Salivary Glands;   Metastatic Adenoid Cystic Carcinoma of the Salivary Glands;   Salivary Gland Cancers;   ACC
Intervention: Drug: Dovitinib
16 Unknown  Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
Conditions: Cancer of the Head and Neck;   Carcinoma, Adenoid Cystic
Intervention: Drug: Imatinib
17 Active, not recruiting Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Stage III Major Salivary Gland Carcinoma;   Stage III Oral Cavity Adenoid Cystic Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma;   Tongue Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
18 Completed Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Adenoid Cystic Carcinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Salivary Gland Cancer
Interventions: Drug: bortezomib;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
19 Completed Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Conditions: High-grade Salivary Gland Carcinoma;   High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
20 Not yet recruiting Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
Condition: Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions: Drug: Axitinib;   Other: Observation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.